Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
| العنوان: | Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis |
|---|---|
| المؤلفون: | Maria Roussou, Evangelos Terpos, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Ioannis Kostopoulos, Maria Gavriatopoulou, Bruno Paiva, Dimitrios C. Ziogas, Ioannis P. Trougakos, Ourania E. Tsitsilonis, Efstathios Kastritis, Magdalini Migkou, Nikolaos Kanellias |
| المصدر: | Blood Cancer Journal, Vol 8, Iss 5, Pp 1-4 (2018) Blood Cancer Journal |
| بيانات النشر: | Springer Nature, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Pathology, medicine.medical_specialty, Neoplasm, Residual, Biopsy, lcsh:RC254-282, Immunophenotyping, Flow cytometry, 03 medical and health sciences, 0302 clinical medicine, Text mining, Correspondence, Biomarkers, Tumor, AL amyloidosis, Humans, Medicine, Immunoglobulin Light-chain Amyloidosis, In patient, medicine.diagnostic_test, business.industry, Amyloidosis aims, Hematology, Free light chain (FLCs), Flow Cytometry, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Minimal residual disease, Oncology, 030220 oncology & carcinogenesis, business, Hematologic responses (hemCR), Biomarkers, 030215 immunology |
| الوصف: | The treatment of light chain (AL) amyloidosis aims to completely eliminate the toxic light chain production, as assessed by sensitive serum- or urine-based methods such as immunofixation and free light chain (FLCs) quantification. Complete hematologic responses (hemCR) can be achieved in a significant proportion of patients with AL, either with conventional therapies or with high-dose melphalan, and are associated with better overall survival and improved organ function. However, hematologic relapses still occur and organ function may continue to deteriorate due to small residual clones that may lead to disease recurrence and/or may produce very small amounts of toxic light chains which are undetectable by conventional techniques. Next-generation flow cytometry (NGF) is a very sensitive method for the evaluation of minimal residual disease (MRD) and one of the standard methods for the assessment of MRD in patients with multiple myeloma (MM), reflected in the new response assessment criteria2. Patients with MM who are negative for MRD have significantly improved progression-free and overall survival, even among those who have achieved a CR3,4. Such data are sparse in patients with AL amyloidosis, although the presence of MRD may prove a crucial factor for delayed organ response or deterioration of organ function despite conventional hemCR. The aim of the current study was to evaluate feasibility and applicability of MRD by NGF in patients with AL at hemCR. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5768fa0383eb918263f857f72cb943abTest https://hdl.handle.net/10171/65652Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5768fa0383eb918263f857f72cb943ab |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |